SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
Nora Therapeutics, Inc. is a biotechnology company that focuses on developing therapeutics to address unmet needs in reproductive medicine. Its product includes NT100, a biologic agent similar to a naturally occurring protein in the female reproductive tract that may reduce the risk of miscarriage by optimizing maternal-fetal immune tolerance in women who have a history of unexplained recurrent miscarriage. Nora Therapeutics, Inc. was formerly known as Nora, LLC. The company was founded in 1992 and is based in Palo Alto, California.
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.
NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, provides real-time volumetric images of the esophagus and bile duct, enabling healthcare professionals across various specialties, including gastroenterology and pulmonology, to conduct advanced imaging procedures. This technology allows for high-resolution, cross-sectional views that facilitate accurate diagnoses and effective therapies during medical procedures. NinePoint aims to enhance the efficiency of patient care by integrating access to imaging, diagnosis, and treatment in a single procedure, ultimately improving patient outcomes and reducing healthcare costs. The company markets its products through distributors both domestically and internationally. Established in 2008, NinePoint Medical was formerly known as Convergence Devices, Inc. and underwent a name change in 2009.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.
DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
TOPICA Pharmaceuticals, Inc. is a privately held clinical research stage pharmaceutical company focused on developing luliconazole for the treatment of onychomycosis, fungal infections of the nail. More than 35 million Americans are estimated to suffer from onychomycosis for which treatment options are limited. In addition to luliconazole’s highly potent anti-fungal activity and excellent safety profile, the molecule is able to rapidly cross the nail plate reaching the site of the infection in the nail bed. In a Phase 1/2a clinical trial completed in 2011, TOPICA demonstrated the ability of its 3 proprietary 10 percent luliconazole solution to rapidly cross the nail plate and was well tolerated by patients. The company is now focused on conducting a robust dose finding and proof of efficacy study with luliconazole in onychomycosis starting in mid 2012 with the goal of making luliconazole the first highly effective and safe topical therapy for the treatment of onychomycosis.
Azelon Pharmaceuticals, formerly Zelos Therapeutics, a West Conshohocken, PA-based company focused on the development of novel formulations for the treatment of osteoporosis.
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
SurePoint Medical, LLC is a Lawrence, Kansas-based company that specializes in providing mail-order diabetes supplies across the United States. The company focuses on delivering essential products to individuals managing diabetes, ensuring they have convenient access to the supplies they need for effective self-care. With a commitment to customer service and efficient delivery, SurePoint Medical aims to improve the quality of life for those living with diabetes by streamlining the process of obtaining necessary medical supplies.
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.
NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, provides real-time volumetric images of the esophagus and bile duct, enabling healthcare professionals across various specialties, including gastroenterology and pulmonology, to conduct advanced imaging procedures. This technology allows for high-resolution, cross-sectional views that facilitate accurate diagnoses and effective therapies during medical procedures. NinePoint aims to enhance the efficiency of patient care by integrating access to imaging, diagnosis, and treatment in a single procedure, ultimately improving patient outcomes and reducing healthcare costs. The company markets its products through distributors both domestically and internationally. Established in 2008, NinePoint Medical was formerly known as Convergence Devices, Inc. and underwent a name change in 2009.
Pathwork Diagnostics, located in Redwood City, California, specializes in molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. The test leverages genomic information from a tumor to enhance diagnostic precision and can be applied to various specimen types, including frozen tissue and formalin-fixed, paraffin-embedded samples. Through its advanced diagnostic solutions, Pathwork Diagnostics aims to improve clinical outcomes in cancer care.
Complete Genomics is a developer of a DNA sequencing platform that focuses on human genome sequencing and analysis. The company offers high-quality and affordable DNA sequencing services, which facilitate large-scale research into the genetic mechanisms that influence drug responses and complex diseases. By integrating proprietary sequencing technology with advanced informatics and data management software, Complete Genomics provides customers with readily usable data for genome-based research. This combination of innovative technology and a disruptive approach positions the company to significantly impact the field of DNA sequencing.
DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..
Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.
Neomend, Inc., a biomedical device company, engages in the development and commercialization of surgical wound healing products. Its platform technology, Pro/PEG, is a bioadhesive polymer hydrogel. NeoMend engages in commercialization of the combination wound sealant and adhesion barrier product that can be delivered during minimally invasive/laparoscopic procedures. Neomend, Inc. was founded in 1999 and is based in Irvine, California.
DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine's lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.
Complete Genomics is a developer of a DNA sequencing platform that focuses on human genome sequencing and analysis. The company offers high-quality and affordable DNA sequencing services, which facilitate large-scale research into the genetic mechanisms that influence drug responses and complex diseases. By integrating proprietary sequencing technology with advanced informatics and data management software, Complete Genomics provides customers with readily usable data for genome-based research. This combination of innovative technology and a disruptive approach positions the company to significantly impact the field of DNA sequencing.
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics to address significant medical needs and patient dissatisfaction. The company is actively involved in in-licensing, developing, and marketing products, particularly in the central nervous system therapeutic area. Somaxon is currently promoting Silenor®, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, the company has experience in developing products for other medical conditions, including middle ear infections, head lice, and cough and cold.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for patients suffering from cataracts, including those with presbyopia. The company has developed the Synchrony dual optic accommodating intraocular lens (IOL), which aims to enhance visual clarity at near, intermediate, and distance ranges without requiring glasses or contact lenses. To streamline the surgical process, the Synchrony IOL is offered in a pre-loaded injector, minimizing lens handling during implantation. This patented technology has received CE Mark approval in Europe and is currently in clinical trials in the United States.
Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.
DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..
Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
SurgRx, Inc is a developer of laparoscopic vessel fusion tools for surgical hemostasis. The company develops tissue sealing and hemostasis systems for laparoscopic and open surgery. It also offers EnSeal, a tissue sealing and hemostasis system that allows surgeons to seal and transect vessels, pedicles, and tissue bundles to achieve surgical hemostasis. SurgRx, Inc is based in Redwood City, California.
Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.
Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.
Neomend, Inc., a biomedical device company, engages in the development and commercialization of surgical wound healing products. Its platform technology, Pro/PEG, is a bioadhesive polymer hydrogel. NeoMend engages in commercialization of the combination wound sealant and adhesion barrier product that can be delivered during minimally invasive/laparoscopic procedures. Neomend, Inc. was founded in 1999 and is based in Irvine, California.
Roxro Pharma, Inc. is a biopharmaceutical company focused on developing innovative drugs for pain management. Founded in 1999 and based in Menlo Park, California, the company specializes in intranasal formulations aimed at addressing various types of pain. Its primary products include ROX-888, designed for the treatment of dental and postoperative pain, and ROX-828, a non-opioid and non-triptan formulation targeted at migraine relief. Through its research and development efforts, Roxro Pharma aims to provide effective alternatives for individuals suffering from pain.
SurgRx, Inc is a developer of laparoscopic vessel fusion tools for surgical hemostasis. The company develops tissue sealing and hemostasis systems for laparoscopic and open surgery. It also offers EnSeal, a tissue sealing and hemostasis system that allows surgeons to seal and transect vessels, pedicles, and tissue bundles to achieve surgical hemostasis. SurgRx, Inc is based in Redwood City, California.
Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.
Aspen MedTech
Venture Round in 2007
Aspen Medtech, a Bellevue, WA-based medical device incubator.
Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.
Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for patients suffering from cataracts, including those with presbyopia. The company has developed the Synchrony dual optic accommodating intraocular lens (IOL), which aims to enhance visual clarity at near, intermediate, and distance ranges without requiring glasses or contact lenses. To streamline the surgical process, the Synchrony IOL is offered in a pre-loaded injector, minimizing lens handling during implantation. This patented technology has received CE Mark approval in Europe and is currently in clinical trials in the United States.
Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine's lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
Pathwork Diagnostics, located in Redwood City, California, specializes in molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. The test leverages genomic information from a tumor to enhance diagnostic precision and can be applied to various specimen types, including frozen tissue and formalin-fixed, paraffin-embedded samples. Through its advanced diagnostic solutions, Pathwork Diagnostics aims to improve clinical outcomes in cancer care.
Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.
DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Hansen Medical, Inc. develops and manufactures advanced medical robotics focused on the precise positioning, manipulation, and control of catheters and catheter-based technologies. The company offers several key products, including the Sensei systems and Artisan Control Catheters, which are utilized during electrophysiology procedures to enhance the control and placement of mapping catheters. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that aids physicians in catheter navigation with enhanced three-dimensional visual feedback. The Magellan Robotic System is another significant offering, featuring a robotically steerable catheter that allows for remote navigation and therapeutic device delivery. Hansen Medical markets its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and based in Mountain View, California, the company is a subsidiary of Auris Surgical Robotics, Inc.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
Roxro Pharma, Inc. is a biopharmaceutical company focused on developing innovative drugs for pain management. Founded in 1999 and based in Menlo Park, California, the company specializes in intranasal formulations aimed at addressing various types of pain. Its primary products include ROX-888, designed for the treatment of dental and postoperative pain, and ROX-828, a non-opioid and non-triptan formulation targeted at migraine relief. Through its research and development efforts, Roxro Pharma aims to provide effective alternatives for individuals suffering from pain.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.
Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.
Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics to address significant medical needs and patient dissatisfaction. The company is actively involved in in-licensing, developing, and marketing products, particularly in the central nervous system therapeutic area. Somaxon is currently promoting Silenor®, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, the company has experience in developing products for other medical conditions, including middle ear infections, head lice, and cough and cold.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Allux Medical
Series B in 2005
Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.
Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs.
The company has assembled an experienced team along with a portfolio of clinical and commercial stage programs with the goal of bringing important new treatment options to patients.
Allux Medical
Series A in 2004
Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.
SurgRx, Inc is a developer of laparoscopic vessel fusion tools for surgical hemostasis. The company develops tissue sealing and hemostasis systems for laparoscopic and open surgery. It also offers EnSeal, a tissue sealing and hemostasis system that allows surgeons to seal and transect vessels, pedicles, and tissue bundles to achieve surgical hemostasis. SurgRx, Inc is based in Redwood City, California.
Trubion Pharmaceuticals
Series B in 2004
Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.
Rejuvenon a biopharmaceutical company committed developing and commercializing promising compounds for treatment of oncologic diseases.
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers aimed at preventing and treating both chronic and acute diseases. Founded in 2000, the company has developed various product candidates, including ARC1779, which targets thrombotic microangiopathies and is intended for use in carotid endarterectomy surgical procedures. In addition to its work in thrombotic conditions, Archemix is also involved in developing aptamers for cardiovascular, hematology, and oncology diseases, contributing to a diverse portfolio of therapeutic solutions.
Jazz Pharmaceuticals is a biopharmaceutical company specializing in the identification, development, and commercialization of products for neurology and psychiatry, primarily in the United States. The company's notable products include Xyrem, which treats cataplexy and excessive daytime sleepiness in narcolepsy patients; Cystadane, for homocystinuria; and Antizol, used for ethylene glycol and methanol poisoning. Jazz Pharmaceuticals is advancing several late-stage candidates such as Luvox CR, an extended-release formulation for obsessive-compulsive disorder and social anxiety disorder, and JZP-6, a liquid form of sodium oxybate aimed at treating fibromyalgia. Its clinical pipeline features JZP-4, targeting epilepsy and bipolar disorder; JZP-8, for acute seizure clusters; JZP-7, for restless legs syndrome; and JZP-2, designed for panic attacks in panic disorder. The company maintains a product development and licensing agreement with Antares Pharma. Founded in 2003, Jazz Pharmaceuticals is headquartered in Palo Alto, California.
Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.
Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Rinat Neuroscience, founded in 2001 following a spin-out from Genentech, focuses on developing protein-based therapeutics for various neurological diseases and disorders. The company leverages significant research and development resources previously invested by Genentech to advance its pioneering efforts in antibody drug development. Rinat is dedicated to creating innovative treatments for conditions such as pain, Alzheimer's disease, obesity, diabetes, and neuropathies. Additionally, it is engaged in developing novel therapies aimed at modifying disease progression by targeting and protecting specific populations of neurons affected by these diseases. Through its work, Rinat Neuroscience seeks to improve patient outcomes in the field of neurology.
Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
Biospect, Inc. is developing minimally invasive technology for identifying and assaying protein biomarker patterns that reflect and differentiate biological states. The integrated Biospect system consists of proprietary separations, detection and informatics technologies, and is targeted for use in diagnosing and managing disease or drug development. Biospect is backed by Advent Venture Partners, Prospect Venture Partners, Venrock Associates and Versant Ventures and was incubated by Prospect Venture Partners.
Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers aimed at preventing and treating both chronic and acute diseases. Founded in 2000, the company has developed various product candidates, including ARC1779, which targets thrombotic microangiopathies and is intended for use in carotid endarterectomy surgical procedures. In addition to its work in thrombotic conditions, Archemix is also involved in developing aptamers for cardiovascular, hematology, and oncology diseases, contributing to a diverse portfolio of therapeutic solutions.
Infinity Pharmaceuticals, Inc. is engaged in the discovery and development of medicines aimed at treating cancer and related conditions in the United States. The company's lead product candidate is IPI-504 (retaspimycin hydrochloride), an intravenously administered small molecule inhibitor of heat shock protein 90 (Hsp90). Infinity is conducting several clinical trials for IPI-504, including a Phase II trial in combination with Herceptin for HER2-positive metastatic breast cancer and another Phase II trial for advanced non-small cell lung cancer. Additionally, the company is exploring IPI-493, an orally delivered Hsp90 inhibitor, as well as IPI-926 and IPI-940, which target advanced solid tumors and pain management, respectively. Infinity Pharmaceuticals has established strategic alliances with various partners, including Purdue Pharmaceutical Products and Novartis Institute for BioMedical Research, to advance its drug development efforts. The company is headquartered in Cambridge, Massachusetts.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Signature BioScience
Series E in 2002
Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.
Metreo delivers profit optimization software that enables Global 2000 manufacturers, distributors and service providers to improve margins by taking time out, taking cost out and putting margin back into the pricing process. Metreo is the first company to provide an integrated price planning and price execution solution to set appropriate price targets, evaluate customer sales requests, recommend profitable responses, and negotiate winning deals. Based in Palo Alto, CA.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.